NASDAQ AKBA opened at $2.38 on Thursday. Akebia Therapeutics has a 12 month low of $0.80 and a 12 month high of $2.48. The stock’s 50 day moving average is $1.95 and its 200 day moving average ...

$240,000 of AKEBIA THERAPEUTICS INC. lobbying was just disclosed, from Q4 of 2024, in a new Lobbying Disclosure Act filing. This included lobbying on issues like: "H.R. 4366, Consolidated ...

Akebia Therapeutics has a 1-year low of $0.80 and a 1-year high of $2.48. Akebia Therapeutics ( NASDAQ:AKBA – Get Free Report ) last posted its quarterly earnings data on Thursday, November 7th.

On Wednesday, H.C. Wainwright analysts maintained a Buy rating on Akebia Therapeutics (NASDAQ:AKBA). The firm's endorsement follows Akebia's announcement on January 13 that the U.S. commercial ...

On Tuesday, H.C. Wainwright maintained a Buy rating on Akebia Therapeutics (NASDAQ:AKBA) stock with a steady price target of $7.50, significantly above the current trading price of $1.88.

Analyst Ed Arce of H.C. Wainwright maintained a Buy rating on Akebia Therapeutics (AKBA – Research Report), retaining the price target of $7.50. Discover outperforming stocks and invest smarter ...

Akebia (AKBA) Therapeutics announced multiple positive business updates. As of January, Vafseo tablets are available in the U.S. for adult patients with anemia due to chronic kidney disease on ...

New Commercial Supply Contracts for Vafseo® (vadadustat) secured, bringing availability and dialysis organization coverage to nearly 100% of patients on dialysis in U.S. Akebia also announced its ...

The game sees players traveling around a One Piece-inspired world in search of hidden treasures and mysterious fruits that grant superhuman powers. Every Blox Fruit is unique, but some are just too ...